Home › Myasthenia Gravis
Myasthenia Gravis clinical trials recruiting in the U.S.
41 studies for Myasthenia Gravis are recruiting participants at sites across the United States.
Myasthenia gravis (MG) is an autoimmune disease that weakens the muscles under your control. Find out about MG causes, symptoms, and treatment.
Cities with the most studies
- Tampa, FL11 studies
- Houston, TX10 studies
- Durham, NC8 studies
- Columbus, OH8 studies
- Boca Raton, FL8 studies
- Milwaukee, WI7 studies
- Washington, DC6 studies
- Detroit, MI6 studies
- Miami, FL6 studies
- New York City, NY6 studies
- Philadelphia, PA6 studies
- Portland, OR6 studies
- Austin, TX6 studies
- Boston, MA6 studies
- Scottsdale, AZ5 studies
- Charleston, SC5 studies
- Cincinnati, OH5 studies
- Dallas, TX5 studies
- San Francisco, CA5 studies
- Orange, CA5 studies
- Aurora, CO5 studies
- Chattanooga, TN5 studies
- Jacksonville, FL5 studies
- St. Louis, MO5 studies
- Kansas City, KS5 studies
- Chicago, IL4 studies
- New Haven, CT4 studies
- Lexington, KY4 studies
- Port Charlotte, FL4 studies
- Mountain View, CA4 studies
- Amherst, NY4 studies
- Columbia, MO4 studies
- Orlando, FL4 studies
- Raleigh, NC3 studies
- Knoxville, TN3 studies
- Augusta, GA3 studies
- Lansing, MI3 studies
- Clearwater, FL3 studies
- Phoenix, AZ3 studies
- Los Angeles, CA3 studies
By state
- Arizona7 studies
- California19 studies
- Colorado9 studies
- Connecticut6 studies
- District of Columbia6 studies
- Florida20 studies
- Georgia3 studies
- Illinois10 studies
- Indiana3 studies
- Kansas6 studies
- Kentucky5 studies
- Massachusetts10 studies
- Michigan11 studies
- Minnesota3 studies
- Missouri5 studies
- Nevada3 studies
- New York12 studies
- North Carolina12 studies
- Ohio12 studies
- Oregon7 studies
- Pennsylvania6 studies
- South Carolina6 studies
- Tennessee9 studies
- Texas16 studies
- Washington4 studies
- Wisconsin7 studies
Recently updated studies
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Nov 13, 2026 · NCT07039916A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07465289A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07463521A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT04951622A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
RecruitingPhase 2/3
Ages 2 to 17 · All sexes · Updated Nov 4, 2026 · NCT05265273ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07673627Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Nov 3, 2026 · NCT07217587A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Oct 30, 2026 · NCT07647510A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07673744Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2026 · NCT01793168A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06680037ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07294170A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
RecruitingPhase 2
Ages 2 to 17 · All sexes · Updated Oct 23, 2026 · NCT06987539Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06626919Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06463587RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Oct 19, 2026 · NCT06359041Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Oct 19, 2026 · NCT07304154Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07787247ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07284420Zilucoplan for Severe gMG Exacerbations
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07215949Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06414954AXIS MG Patient Registry
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07761026Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 64 · Women · Updated Aug 11, 2026 · NCT06940323MuSK Myasthenia 1000 Study
RecruitingObservational study
Ages 7 to 99 · All sexes · Updated Aug 5, 2026 · NCT06259071Study of Aritinercept in Patients With Generalized Myasthenia Gravis
RecruitingPhase 1/2
Ages 18 to 85 · All sexes · Updated Aug 3, 2026 · NCT07596901From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.